105 related articles for article (PubMed ID: 25229053)
21. FLT: measuring tumor cell proliferation in vivo with positron emission tomography and 3'-deoxy-3'-[18F]fluorothymidine.
Salskov A; Tammisetti VS; Grierson J; Vesselle H
Semin Nucl Med; 2007 Nov; 37(6):429-39. PubMed ID: 17920350
[TBL] [Abstract][Full Text] [Related]
22. Role of PET quantitation in the monitoring of cancer response to treatment: Review of approaches and human clinical trials.
Doot RK; McDonald ES; Mankoff DA
Clin Transl Imaging; 2014 Aug; 2(4):295-303. PubMed ID: 25229053
[TBL] [Abstract][Full Text] [Related]
23. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
24. Monitoring of anti-cancer treatment with (18)F-FDG and (18)F-FLT PET: a comprehensive review of pre-clinical studies.
Jensen MM; Kjaer A
Am J Nucl Med Mol Imaging; 2015; 5(5):431-56. PubMed ID: 26550536
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography.
Yap CS; Czernin J; Fishbein MC; Cameron RB; Schiepers C; Phelps ME; Weber WA
Chest; 2006 Feb; 129(2):393-401. PubMed ID: 16478857
[TBL] [Abstract][Full Text] [Related]
26. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG.
Chen W; Cloughesy T; Kamdar N; Satyamurthy N; Bergsneider M; Liau L; Mischel P; Czernin J; Phelps ME; Silverman DH
J Nucl Med; 2005 Jun; 46(6):945-52. PubMed ID: 15937304
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of [
Jiang H; Zhang R; Jiang H; Zhang M; Guo W; Feng G; Pan W; Xu H; Wang S
Nucl Med Biol; 2019; 72-73():36-44. PubMed ID: 31330410
[TBL] [Abstract][Full Text] [Related]
28. Multicenter trials using ¹⁸F-fluorodeoxyglucose (FDG) PET to predict chemotherapy response: effects of differential measurement error and bias on power calculations for unselected and enrichment designs.
Kurland BF; Doot RK; Linden HM; Mankoff DA; Kinahan PE
Clin Trials; 2013; 10(6):886-95. PubMed ID: 24169628
[TBL] [Abstract][Full Text] [Related]
29. A partial volume effect correction tailored for 18F-FDG-PET oncological studies.
Gallivanone F; Canevari C; Gianolli L; Salvatore C; Della Rosa PA; Gilardi MC; Castiglioni I
Biomed Res Int; 2013; 2013():780458. PubMed ID: 24163819
[TBL] [Abstract][Full Text] [Related]
30. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
Gebhart G; Gámez C; Holmes E; Robles J; Garcia C; Cortés M; de Azambuja E; Fauria K; Van Dooren V; Aktan G; Coccia-Portugal MA; Kim SB; Vuylsteke P; Cure H; Eidtmann H; Baselga J; Piccart M; Flamen P; Di Cosimo S
J Nucl Med; 2013 Nov; 54(11):1862-8. PubMed ID: 24092940
[TBL] [Abstract][Full Text] [Related]
31. State-of-the-Art Research on "Lymphomas: Role of Molecular Imaging for Staging, Prognostic Evaluation, and Treatment Response".
Kostakoglu L; Cheson BD
Front Oncol; 2013 Sep; 3():212. PubMed ID: 24027671
[TBL] [Abstract][Full Text] [Related]
32. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy.
Usmanij EA; de Geus-Oei LF; Troost EG; Peters-Bax L; van der Heijden EH; Kaanders JH; Oyen WJ; Schuurbiers OC; Bussink J
J Nucl Med; 2013 Sep; 54(9):1528-34. PubMed ID: 23864719
[TBL] [Abstract][Full Text] [Related]
33. 3'-Deoxy-3'-18F-fluorothymidine PET for the early prediction of response to leucovorin, 5-fluorouracil, and oxaliplatin therapy in patients with metastatic colorectal cancer.
Hong YS; Kim HO; Kim KP; Lee JL; Kim HJ; Lee SJ; Lee SJ; Oh SJ; Kim JS; Ryu JS; Moon DH; Kim TW
J Nucl Med; 2013 Aug; 54(8):1209-16. PubMed ID: 23804324
[TBL] [Abstract][Full Text] [Related]
34. Impact of different standardized uptake value measures on PET-based quantification of treatment response.
Vanderhoek M; Perlman SB; Jeraj R
J Nucl Med; 2013 Aug; 54(8):1188-94. PubMed ID: 23776199
[TBL] [Abstract][Full Text] [Related]
35. Radionuclide methods for breast cancer staging.
Lee JH
Semin Nucl Med; 2013 Jul; 43(4):294-8. PubMed ID: 23725991
[TBL] [Abstract][Full Text] [Related]
36. Limits of [18F]-FLT PET as a biomarker of proliferation in oncology.
McKinley ET; Ayers GD; Smith RA; Saleh SA; Zhao P; Washington MK; Coffey RJ; Manning HC
PLoS One; 2013; 8(3):e58938. PubMed ID: 23554961
[TBL] [Abstract][Full Text] [Related]
37. ¹⁸F-FDG PET/CT-based treatment response evaluation in locally advanced rectal cancer: a prospective validation of long-term outcomes.
Calvo FA; Sole CV; de la Mata D; Cabezón L; Gómez-Espí M; Alvarez E; Madariaga P; Carreras JL
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):657-67. PubMed ID: 23436067
[TBL] [Abstract][Full Text] [Related]
38. Changes in (18)F-fluorothymidine and (18)F-fluorodeoxyglucose positron emission tomography imaging in patients with head and neck cancer treated with chemoradiotherapy.
Hoshikawa H; Mori T; Kishino T; Yamamoto Y; Inamoto R; Akiyama K; Mori N; Nishiyama Y
Ann Nucl Med; 2013 May; 27(4):363-70. PubMed ID: 23378102
[TBL] [Abstract][Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
